Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

AbbVie (NY:ABBV)

217.61 -0.73 (-0.33%)
Official Closing Price Updated: 4:10 PM EDT, Sep 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Tesla's Quality Score Tumbles, While Taiwan Semiconductor's Growth Rating Soars
Daily stock price moves often dominate headlines, but shifts in fundamental ranking scores can reveal a deeper story. This week, Benzinga's proprietary Growth data highlighted major swings among... 
Via Benzinga
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever.
Sit back and let the income roll in with this great exchange-traded fund. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
1 Profitable Stock Worth Investigating and 2 That Underwhelm
Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential. 
Via StockStory
Jackson Hole Symposium 2025: The Fed Signals a Pivotal Shift Towards Easing
The annual Jackson Hole Economic Policy Symposium, a highly anticipated gathering of global central bankers, finance ministers, and leading economists, is currently underway in Wyoming. This year's... 
Via MarketMinute
Topics Bonds Credit Cards Economy
All Eyes on Jackson Hole: Will Jerome Powell Signal Imminent Rate Cuts?
Global financial markets are on tenterhooks, fixated on the highly anticipated speech by Federal Reserve Chair Jerome Powell at the annual Jackson Hole Economic Symposium. Investors are keenly awaiting... 
Via MarketMinute
Topics Bonds Credit Cards Economy
A Congress Member Bought Up To $1.17M In AbbVie Stock: Here's What You Need To Know
 
Via Benzinga
AbbVie's Patch Baldness Study Finds High Hair Coverage Rates With Investigational Drug Upadacitinib
AbbVie's Rinvoq Phase 3 trial showed strong efficacy in severe alopecia areata, with many patients achieving significant scalp hair regrowth by week 24. 
Via Benzinga
AbbVie’s Investigational Drug For Alopecia Yields Positive Outcomes In Late-Stage Study
Via Stocktwits
2 High-Yield Dividend Stocks to Buy in August and Hold for a Decade or Longer
These high-yield dividend stocks are built to last. 
Via The Motley Fool
Topics Intellectual Property
Q2 Earnings Highlights: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers. 
Via StockStory
Topics Artificial Intelligence
Jackson Hole Symposium Looms: Why Investors Are Holding Their Breath for Powell's Remarks
The financial world is abuzz with anticipation as the annual Jackson Hole Economic Symposium draws near, an exclusive gathering hosted by the Federal Reserve Bank of Kansas City in the serene mountains... 
Via MarketMinute
Topics Bonds Climate Change Economy
Federal Reserve Poised for September Rate Cut Amidst High Market Expectations and Powell's Jackson Hole Address
Investor sentiment is overwhelmingly pointing towards a significant shift in the Federal Reserve's monetary policy, with a near-certainty of a 25-basis-point interest rate cut anticipated at its... 
Via MarketMinute
Topics Bonds Credit Cards Economy
If You'd Invested $1,000 in AbbVie Stock 10 Years Ago, Here's How Much You'd Have Today
You'd be sitting pretty right now. 
Via The Motley Fool
Topics Intellectual Property
Marjorie Taylor Greene Keeps Buying UnitedHealth Stock Along With Fellow Investors Buffett And Burry
Marjorie Taylor Greene may have another winning stock trade with a new filing showing a purchase of UnitedHealth stock. 
Via Benzinga
Here's How Much $100 Invested In AbbVie 5 Years Ago Would Be Worth Today
 
Via Benzinga
3 Dividend Stocks to Double Up On Right Now
These stocks offer great dividends and more. 
Via The Motley Fool
Topics Economy Government World Trade
1 Cash-Producing Stock with Exciting Potential and 2 We Avoid
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
Topics Economy
Fed Rate Cut Hopes Fuel Market Rally: Inflation Data Steers September Expectations
Optimism has surged through financial markets as recent economic data, particularly the July Consumer Price Index (CPI), has significantly bolstered expectations for a 25-basis-point interest rate cut... 
Via MarketMinute
Topics Bonds Credit Cards Economy
These S&P500 stocks are moving in today's session
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Inflation Report Sparks Global Rally: How Tame CPI is Reshaping Market Expectations
A surprisingly subdued July Consumer Price Index (CPI) report has sent ripples of optimism across global financial markets, igniting a worldwide rally and significantly recalibrating expectations for... 
Via MarketMinute
Topics Bonds Credit Cards Economy
ABBV Q2 Deep Dive: Immunology and Neuroscience Growth Outpace Aesthetics, Guidance Trimmed
Pharmaceutical company AbbVie (NYSE:ABBV) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, with sales up 6.6% year on year to $15.42 billion. Its non-GAAP profit of $2.97 per share... 
Via StockStory
My 3 Favorite Stocks to Buy Right Now
These tried-and-true businesses are performing well against a volatile backdrop. 
Via The Motley Fool
Topics Intellectual Property
4 of My Favorite Dividend Stocks for the Next 5 Years
All four pay safe, reliable, and growing dividends. 
Via The Motley Fool
3 Stocks Retirees Should Absolutely Love
These stocks check off all the boxes for investors no longer receiving a paycheck. 
Via The Motley Fool
Topics Economy Retirement
Is the Vanguard Value ETF the Simplest Way to Consistently Collect More Passive Income Than the S&P 500?
This ultra-low-cost ETF is an excellent way to invest in large-cap value stocks, many of which pay dividends. 
Via The Motley Fool
Topics ETFs Regulatory Compliance Stocks
3 Market-Beating Stocks with Solid Fundamentals
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta year in and year out often become the legends... 
Via StockStory
AbbVie Inclusion In Medicare Drug Talks Fails To Justify Lawsuit, Court Rules
The federal court dismissed a lawsuit from business chambers over the Medicare drug price negotiation program. 
Via Benzinga
Topics Lawsuit
Federal Reserve Poised for Rate Cuts as Economic Headwinds Mount, Tariffs Complicate Outlook
Financial markets are currently pricing in a high likelihood of the Federal Reserve initiating interest rate cuts before the year-end, a significant shift in monetary policy that reflects growing... 
Via MarketMinute
Topics Bankruptcy Economy Government
Genmab/AbbVie Partnered Blood Cancer Combination Drug Cuts Risk Of Disease Progression By 79%
Genmab reported strong Phase 3 trial results for epcoritamab in FL, secured FDA priority review, and raised its 2025 sales outlook after Q2 beat. 
Via Benzinga
Trump Threatens Pharma With Potential 250% Tariffs In 18 Months: 'We Want Pharmaceuticals Made In Our Country'
President Donald Trump has indicated the possibility of imposing tariffs on imported pharmaceuticals that could rise up to 250%, indicating the highest rate he has proposed so far. 
Via Benzinga
Topics Government World Trade
< Previous 1 2 3 4 5 6 7 8 9
...
85 86 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.